Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Caitlin E. Cox

November 18, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

L.A. McKeown

September 13, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2018

Shelley Wood

August 01, 2018

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

Advertisement

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

CMS Announces Negotiated Medicare Prices for First 10 Drugs

June 2024 Dispatch for the CV Team

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Dapagliflozin Boosts Health Status Across LVEF Range

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Making the Case for Sex-Specific CVD Guidelines

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

TCTMD’s Top 10 Most Popular Stories for November 2018

TCTMD’s Top 10 Most Popular Stories for July 2018

Generic ARBs Linked to Increased Adverse Events

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content